4D Molecular Therapeutics’ (FDMT) “Sell (D-)” Rating Reiterated at Weiss Ratings

4D Molecular Therapeutics (NASDAQ:FDMT)‘s stock had its “sell (d-)” rating restated by analysts at Weiss Ratings in a research report issued on Tuesday,Weiss Ratings reports.

Several other analysts also recently issued reports on the company. Bank of America decreased their target price on 4D Molecular Therapeutics from $42.00 to $40.00 and set a “buy” rating on the stock in a research note on Monday, March 10th. Morgan Stanley lowered their target price on shares of 4D Molecular Therapeutics from $8.00 to $6.00 and set an “underweight” rating on the stock in a report on Monday, January 13th. BMO Capital Markets cut shares of 4D Molecular Therapeutics from an “outperform” rating to a “market perform” rating and cut their target price for the company from $40.00 to $15.00 in a research note on Monday, January 13th. Leerink Partners decreased their price target on shares of 4D Molecular Therapeutics from $31.00 to $27.00 and set an “outperform” rating on the stock in a research note on Monday, January 13th. Finally, Chardan Capital reduced their target price on 4D Molecular Therapeutics from $30.00 to $28.00 and set a “buy” rating on the stock in a report on Tuesday, March 4th. One analyst has rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $26.71.

4D Molecular Therapeutics Trading Down 5.3 %

NASDAQ FDMT opened at $2.51 on Tuesday. The stock has a market cap of $116.22 million, a price-to-earnings ratio of -0.88 and a beta of 2.89. 4D Molecular Therapeutics has a 12 month low of $2.46 and a 12 month high of $29.22. The company’s 50 day moving average is $4.28 and its two-hundred day moving average is $6.34.

4D Molecular Therapeutics (NASDAQ:FDMT) last released its earnings results on Friday, February 28th. The company reported ($0.90) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.10). Sell-side analysts forecast that 4D Molecular Therapeutics will post -2.84 EPS for the current year.

Institutional Investors Weigh In On 4D Molecular Therapeutics

Several institutional investors have recently made changes to their positions in FDMT. Point72 Asset Management L.P. bought a new stake in 4D Molecular Therapeutics in the third quarter worth about $166,000. State Street Corp raised its holdings in shares of 4D Molecular Therapeutics by 1.8% in the third quarter. State Street Corp now owns 2,116,508 shares of the company’s stock worth $22,879,000 after buying an additional 37,232 shares during the period. Y Intercept Hong Kong Ltd lifted its stake in shares of 4D Molecular Therapeutics by 81.3% during the 3rd quarter. Y Intercept Hong Kong Ltd now owns 24,538 shares of the company’s stock worth $265,000 after acquiring an additional 11,002 shares during the last quarter. Barclays PLC boosted its holdings in 4D Molecular Therapeutics by 141.0% during the 3rd quarter. Barclays PLC now owns 114,848 shares of the company’s stock valued at $1,241,000 after acquiring an additional 67,202 shares during the period. Finally, Marquette Asset Management LLC bought a new position in 4D Molecular Therapeutics in the 4th quarter valued at $116,000. Institutional investors own 99.27% of the company’s stock.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.